Department of Neurosurgery, University Hospital, Albert-Ludwigs-University, Breisacherstr. 64, 79106, Freiburg, Germany.
Kork Epilepsy Center, Landstrasse 1, 77694, Kehl, Germany.
J Neurol. 2018 Mar;265(3):500-509. doi: 10.1007/s00415-017-8700-z. Epub 2018 Jan 6.
To evaluate the impact of postoperative antiepileptic drug (AED) load on seizure control in patients who underwent surgical treatment for pharmacoresistant mesiotemporal lobe epilepsy during the first two postoperative years.
532 consecutive patients (48.7% males and 51.7% females) who underwent surgical treatment for mesiotemporal lobe epilepsy were retrospectively evaluated regarding effects of AED load on seizures control during the first 2 years following epilepsy surgery. We analyzed whether postoperative increases in postoperative AED load are associated with better seizure control in patients initially not seizure free, and if postoperative decreases in postoperative AED load would increase the risk for seizure persistence or recurrence. For statistical analyses, Fisher's exact and Wilcoxon test were applied.
68.9, 64.0 and 59.1% of patients were completely seizure free (Engel Ia) at 3, 12 and 24 months after surgery, respectively. Patients in whom daily drug doses were increased did not have a higher rate of seizure freedom at any of the three follow-up periods. Of 16 patients achieving secondary seizure control at 12 months after surgery, only one did so with an increase in drug load in contrast to 15 patients who experienced a running down of seizures independent of drug load increases. Decreases in drug load did not significantly increase the risk for seizure recurrence. Of postoperatively seizure free patients at 3 months after surgery in whom AED were consequently reduced, 85% remained completely seizure free at 1 year and 76% at 1 year after surgery, respectively, as opposed to 86% each when AED was not reduced (differences n.s.). Mean daily drug load was significantly lower in seizure free patients at 12 and 24 months compared to patients with ongoing seizures.
In this large patient cohort stratified to the epilepsy syndrome neither did a postoperative reduction in drug load significantly increase the risk for seizure relapse nor did increases in drug dosages lead to improved seizure control. Mean drug load was on average lower in seizure free- than non-seizure free patients at 12 and 24 months of follow-up. Secondary seizure control after initial postoperative seizures in > 90% of cases occurred as a running down, independent of an AED increase. Thus, the effect of the surgical intervention rather than the postoperative drug regimen was the key determinant for seizure control. This finding supports a curative role of temporal lobe surgery rather than an effect rendering the majority of patients' pharmacoresponsive with a critical role of the antiepileptic drug regime for seizure control.
评估术后抗癫痫药物(AED)负荷对药物难治性颞叶内侧癫痫患者术后头两年内癫痫发作控制的影响。
回顾性评估了 532 例接受手术治疗的颞叶内侧癫痫患者(男性 48.7%,女性 51.7%),分析术后 AED 负荷增加是否与初始无癫痫发作的患者更好的癫痫发作控制相关,以及术后 AED 负荷减少是否会增加癫痫持续或复发的风险。统计分析采用 Fisher 确切检验和 Wilcoxon 检验。
术后 3、12 和 24 个月时,分别有 68.9%、64.0%和 59.1%的患者完全无癫痫发作(Engel Ia)。在任何三个随访期内,每日药物剂量增加的患者癫痫发作无发作率均无升高。术后 12 个月时,16 例患者获得继发性癫痫控制,其中仅 1 例药物负荷增加,而 15 例患者在不增加药物负荷的情况下癫痫发作减少。药物负荷减少并未显著增加癫痫发作复发的风险。术后 3 个月无癫痫发作的患者中,随后减少 AED 药物剂量,其中 85%在术后 1 年和 76%在术后 1 年时仍完全无癫痫发作,而 AED 药物剂量未减少的患者分别为 86%(差异无统计学意义)。与持续有癫痫发作的患者相比,12 个月和 24 个月时无癫痫发作的患者平均每日药物负荷明显降低。
在本项大型队列研究中,根据癫痫综合征分层,术后药物负荷减少并未显著增加癫痫发作复发的风险,增加药物剂量也不能改善癫痫发作控制。与持续有癫痫发作的患者相比,12 个月和 24 个月时无癫痫发作的患者平均药物负荷更低。初始术后癫痫发作后,>90%的患者出现继发性癫痫控制,与 AED 增加无关。因此,手术干预的效果而不是术后药物治疗方案是癫痫发作控制的关键决定因素。这一发现支持颞叶切除术具有治愈作用,而不是通过药物治疗方案使大多数患者对药物有反应,从而对癫痫发作控制具有关键作用。